From Academia to Industry: Dr. Stephen Brannan’s Journey in Shaping Modern Mental Health Care

episode

Previously titled “From Academia to Pharma: Dr. Stephen Brannan’s Journey in Shaping Modern Mental Health Care” — renamed by the publisher on Aug 11, 2026

The Journal of Clinical Psychiatry Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Living Breakthrough-Minded | Joel Osteen 30 min · 25 Sep 2026 · Joel Osteen Podcast

4AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Week: Trump vs the Press, Meta’s AI Win, and the Turning Political Tide 22 min · 25 Sep 2026 · The Prof G Pod with Scott Galloway

Gabrielle Lyon Part 2 1h 1m · 25 Sep 2026 · unPAUSED with Dr. Mary Claire Haver

Report any issue

Source

Recorded02 Dec 2025

Publisherfeeds.captivate.fm ↗

Handlerec:13871575

Show notes

Dr. Stephen Brannan brings decades of experience from both academic psychiatry and leadership roles at top pharmaceutical companies to the JCP Podcast today. He details his transition from university research to industry, offering a candid look at the forces that drive innovation in mental health care. Dr. Brannan unpacks the complex process of bringing a new drug to market, using his work on treatments like Cobenfy (xanomeline-trospium) as a case study. The discussion covers the critical decisions in clinical trial design, from selecting the right patient populations to establishing meaningful endpoints that satisfy both regulatory bodies and clinical needs. He also addresses some of the most persistent hurdles in psychiatric research including the high placebo response rates that can obscure a drug's true efficacy and the operational complexities of running large, multinational studies. For clinicians seeking to better understand the evidence behind new medications, Dr. Brannan’s insights provide a unique level of enlightenment in the pragmatism, science, and collaboration required to advance patient care.Episode Highlights:00:00 - Introducing Dr. Stephen Brannan01:56 - From Pre-Med Doubts to a Career in Psychiatry06:51 - The "Push and Pull" from Academia to Industry08:50 - Advice for Young Psychiatrists Considering Industry10:56 - Pitfalls and Misconceptions of Pharmaceutical Work14:37 - Balancing Real-World Applicability and Regulatory Realities20:40 - The Science and Strategy Behind Cobenfy22:10 - Understanding and Mitigating the Placebo Effect28:57 - The Role of Expert Steering Committees32:38 - Designing Trials42:37 - The Nuances of Safety Surveillance in Clinical Trials53:27 - Reflections on the Future of Psychiatric TreatmentKey Takeaways:"I will not sacrifice quality for the sake of speed.""I've learned how to talk with people rather than just sort of barking an order.""We're a hell of a lot more alike than we're different.""The better we understand that and we're able to pick treatments based on biomarkers...that's going to make a huge impact.""That's extremely useful in psychiatry because it's rare when you first see somebody...you absolutely know what's going on. It usually takes time and patience and a tolerance for ambiguity.""You also want to be able to talk to people who will tell you what's wrong with your thinking.""You want your beachhead. And your beachhead is...what's the best segment of patients?"Links: Full transcript and show notes: https://www.psychiatrist.com/jcp/ep3-academia-to-pharma-stephen-brannanJournal of Clinical Psychiatry: psychiatrist.com/jcp/ Dr. Stephen Brannan: https://www.linkedin.com/in/steve-brannan-b7376019/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related